EA201990059A1 - Фосфорамидаты для лечения вируса гепатита b - Google Patents
Фосфорамидаты для лечения вируса гепатита bInfo
- Publication number
- EA201990059A1 EA201990059A1 EA201990059A EA201990059A EA201990059A1 EA 201990059 A1 EA201990059 A1 EA 201990059A1 EA 201990059 A EA201990059 A EA 201990059A EA 201990059 A EA201990059 A EA 201990059A EA 201990059 A1 EA201990059 A1 EA 201990059A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- compositions
- phosphoramidates
- hepatitis
- virus
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 150000008298 phosphoramidates Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 229960001997 adefovir Drugs 0.000 abstract 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960000980 entecavir Drugs 0.000 abstract 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 abstract 1
- 229960005311 telbivudine Drugs 0.000 abstract 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 abstract 1
- 229960004556 tenofovir Drugs 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354471P | 2016-06-24 | 2016-06-24 | |
| PCT/US2017/038963 WO2017223421A1 (en) | 2016-06-24 | 2017-06-23 | Phosphoramidates for the treatment of hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990059A1 true EA201990059A1 (ru) | 2019-07-31 |
Family
ID=60783488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990059A EA201990059A1 (ru) | 2016-06-24 | 2017-06-23 | Фосфорамидаты для лечения вируса гепатита b |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11364257B2 (https=) |
| EP (1) | EP3474863A4 (https=) |
| JP (2) | JP2019525905A (https=) |
| KR (1) | KR20190057277A (https=) |
| CN (1) | CN109689065A (https=) |
| AU (1) | AU2017281531A1 (https=) |
| BR (1) | BR112018076913A2 (https=) |
| CA (1) | CA3029315A1 (https=) |
| EA (1) | EA201990059A1 (https=) |
| IL (1) | IL263859B2 (https=) |
| PH (1) | PH12018550207A1 (https=) |
| SG (1) | SG11201811316YA (https=) |
| WO (1) | WO2017223421A1 (https=) |
| ZA (1) | ZA201900156B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202013032YA (en) * | 2014-12-15 | 2021-02-25 | Univ Emory | Phosphoramidates for the treatment of hepatitis b virus |
| EP3752511A4 (en) | 2018-01-10 | 2021-12-29 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11628182B2 (en) * | 2018-04-12 | 2023-04-18 | Zogenix Mds, Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
| WO2020045628A1 (ja) * | 2018-08-31 | 2020-03-05 | ダイキン工業株式会社 | 核酸アナログ及び抗ｂ型肝炎ウイルス剤 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2020103929A1 (zh) * | 2018-11-23 | 2020-05-28 | 正大天晴药业集团股份有限公司 | 低聚核苷酸及前体药物 |
| CN114206896B (zh) | 2019-07-17 | 2024-12-17 | 纽科利制药公司 | 环状脱氧核糖核苷酸化合物 |
| CN110642910B (zh) * | 2019-09-02 | 2020-10-30 | 南开大学 | 胸苷衍生物及其制备方法和用途 |
| WO2021067480A1 (en) * | 2019-10-02 | 2021-04-08 | University Of Washington | Compositions and methods for treatment of hepatitis b virus infection |
| CN111087421B (zh) * | 2019-12-24 | 2022-10-18 | 南京正大天晴制药有限公司 | 一种用于手性药物合成的磷酰胺化合物的制备方法 |
| US12516080B2 (en) | 2020-04-02 | 2026-01-06 | The Regents Of The University Of Michigan | Remdesivir and remdesivir analogs, solutions, and nanoparticle, liposomal, and microparticle compositions for treating viral infections |
| CN113493481B (zh) * | 2020-04-08 | 2025-02-18 | 北京君科华元医药科技有限公司 | 单磷酸恩替卡韦丙氨酰胺酚酯及其医药用途 |
| US12552820B2 (en) | 2020-04-21 | 2026-02-17 | Ligand Pharmaceuticals Incorporated | Benzyloxy phosph(on)ate compounds |
| WO2021253376A1 (zh) * | 2020-06-19 | 2021-12-23 | 南京正大天晴制药有限公司 | 一种用于手性药物合成的磷酰胺化合物的制备方法 |
| WO2022251594A1 (en) * | 2021-05-27 | 2022-12-01 | Antios Therapeutics, Inc. | Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs |
| WO2022256490A2 (en) * | 2021-06-03 | 2022-12-08 | Antios Therapeutics, Inc. | Improved synthesis of phosphoramidates for the treatment of hepatitis b virus |
| CN113501853B (zh) * | 2021-09-13 | 2021-12-07 | 南京颐媛生物医学研究院有限公司 | 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途 |
| CA3243401A1 (en) * | 2022-01-28 | 2023-08-03 | Glaxosmithkline Intellectual Property Development Limited | Polytherapy for the treatment of hepatitis B virus infections |
| CN115260263B (zh) * | 2022-05-23 | 2025-02-21 | 浙江扬厉医药技术有限公司 | 烷基硫芳基克拉夫定磷酰胺类化合物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687931A (en) | 1970-03-19 | 1972-08-29 | Syntex Corp | Halogenated purine and pyrimidine nucleosides and process therefor |
| US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| CA2589935A1 (en) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| EA016838B1 (ru) | 2005-06-07 | 2012-07-30 | Йельский Университет | Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt) |
| US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| ES2398684T3 (es) | 2008-04-23 | 2013-03-21 | Gilead Sciences, Inc. | Análogos de carbanucleósido para el tratamiento antiviral |
| PT2609923T (pt) | 2010-03-31 | 2017-08-30 | Gilead Pharmasset Llc | Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo |
| BR112013005872A2 (pt) | 2010-09-22 | 2019-09-24 | Alios Biopharma Inc | compostos, composição farmacêutica e respectivos usos |
| US20120142627A1 (en) * | 2010-12-06 | 2012-06-07 | Emory University | Monophosphate prodrugs of dapd and analogs thereof |
| US20140315850A1 (en) | 2011-07-19 | 2014-10-23 | Nanjing Molecular Research, Inc. | 2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof |
| BR112015009636A8 (pt) | 2012-10-29 | 2018-04-17 | Cocrystal Pharma Inc | composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto |
| EP2920195A1 (en) | 2012-11-14 | 2015-09-23 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
| WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| AU2014250762A1 (en) * | 2013-04-12 | 2015-10-29 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
| SG10202013032YA (en) * | 2014-12-15 | 2021-02-25 | Univ Emory | Phosphoramidates for the treatment of hepatitis b virus |
-
2017
- 2017-06-23 BR BR112018076913-4A patent/BR112018076913A2/pt not_active IP Right Cessation
- 2017-06-23 EP EP17816278.0A patent/EP3474863A4/en not_active Withdrawn
- 2017-06-23 US US16/312,756 patent/US11364257B2/en active Active
- 2017-06-23 JP JP2018567034A patent/JP2019525905A/ja active Pending
- 2017-06-23 CA CA3029315A patent/CA3029315A1/en active Pending
- 2017-06-23 WO PCT/US2017/038963 patent/WO2017223421A1/en not_active Ceased
- 2017-06-23 EA EA201990059A patent/EA201990059A1/ru unknown
- 2017-06-23 CN CN201780050071.4A patent/CN109689065A/zh active Pending
- 2017-06-23 KR KR1020197002039A patent/KR20190057277A/ko not_active Ceased
- 2017-06-23 SG SG11201811316YA patent/SG11201811316YA/en unknown
- 2017-06-23 AU AU2017281531A patent/AU2017281531A1/en not_active Abandoned
-
2018
- 2018-12-20 IL IL263859A patent/IL263859B2/en unknown
- 2018-12-20 PH PH12018550207A patent/PH12018550207A1/en unknown
-
2019
- 2019-01-09 ZA ZA2019/00156A patent/ZA201900156B/en unknown
-
2022
- 2022-05-06 US US17/738,435 patent/US20220280542A1/en not_active Abandoned
- 2022-05-10 JP JP2022077781A patent/JP2022116024A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190057277A (ko) | 2019-05-28 |
| US20190350954A1 (en) | 2019-11-21 |
| WO2017223421A1 (en) | 2017-12-28 |
| CN109689065A (zh) | 2019-04-26 |
| IL263859A (en) | 2019-01-31 |
| US20220280542A1 (en) | 2022-09-08 |
| JP2022116024A (ja) | 2022-08-09 |
| ZA201900156B (en) | 2019-08-28 |
| US11364257B2 (en) | 2022-06-21 |
| SG11201811316YA (en) | 2019-01-30 |
| AU2017281531A1 (en) | 2019-01-17 |
| PH12018550207A1 (en) | 2019-04-15 |
| EP3474863A1 (en) | 2019-05-01 |
| IL263859B1 (en) | 2023-03-01 |
| JP2019525905A (ja) | 2019-09-12 |
| CA3029315A1 (en) | 2017-12-28 |
| IL263859B2 (en) | 2023-07-01 |
| BR112018076913A2 (pt) | 2019-04-02 |
| EP3474863A4 (en) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990059A1 (ru) | Фосфорамидаты для лечения вируса гепатита b | |
| CY1123324T1 (el) | Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων | |
| WO2016099982A3 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| CY1124742T1 (el) | 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv | |
| EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
| MX2022015257A (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas. | |
| EA201892769A3 (ru) | Сложные диэфиры ациклических нуклеозидфосфонатов | |
| EA201892745A1 (ru) | Фосфорамидатные производные нуклеозида в качестве противораковых агентов | |
| PH12018550150B1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| LT3512863T (lt) | 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu | |
| GEAP202215528A (en) | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| EA201170915A1 (ru) | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций | |
| EA201592184A1 (ru) | 4'-фтор-2'-метилзамещенные нуклеозидные производные | |
| EA201790786A1 (ru) | Комбинированная терапия вызываемой вирусами hbv и hdv инфекции | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| EA201690146A1 (ru) | Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира | |
| EA201892448A1 (ru) | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения | |
| MY191515A (en) | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof | |
| EA202190058A1 (ru) | Композиции фосфорамидатных производных нуклеозидных лекарственных средств | |
| EA201800388A1 (ru) | Макрогетероциклические нуклеозидные производные и их аналоги, получение и применение | |
| EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
| EA201990780A1 (ru) | Твердая форма соединения 4'-тио-2'-фторнуклеозид фосфамида и способ его получения и применения | |
| TR201910305T4 (tr) | Viral enfeksiyonları tedavi etmek için bileşikler. | |
| EA201990834A1 (ru) | Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний | |
| EA201900322A1 (ru) | Циклобутил (s)-2-[[[(r)-2-(6-аминопурин-9-ил)-1-метилэтокси]метилфеноксифосфорил]амино]пропаноаты, способ их получения и применения |